📰 Solid Tumors News
Page 16 - Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.
February 1, 2024
Ritu Salani, MD, discusses impactful efficacy signals from T-DXd in the DESTINY-PanTumor02 study for endometrial cancer, marking a potential breakthrough in this treatment field.
February 1, 2024
Ritu Salani, MD, highlights impactful findings from the DESTINY-PanTumor02 study in patients with cervical cancer, highlighting the promising role of HER2-directed ADCS in this treatment space.
January 31, 2024
Phase II study shows a 32% reduced risk of death compared with standard treatment
January 30, 2024
IGI is introducing a pipeline of three oncology molecules currently undergoing clinical trials, targeting multiple myeloma, acute myeloid leukemia, and solid tumors.
January 25, 2024
Ritu Salani, MD, presents an outline of the treatment landscape for ovarian cancer and underscores encouraging data from the DESTINY-PanTumor02 study, showcasing promising results in this treatment setting.
January 25, 2024
Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.
January 25, 2024
Johnson & Johnson announced today that new clinical and real-world data will be presented via 18 abstracts at the ASCO GU symposium being held January 25-27 in San Francisco, underlining the companys...
January 24, 2024
Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress.
January 24, 2024
/PRNewswire/ -- Johnson & Johnson announced today new clinical and real-world evidence data will be featured in 18 abstracts at this years ASCO GU Symposium...
January 24, 2024
By Karen E. Roman Sirnaomics Ltd., a biopharmaceutical company developing RNAi therapeutics, recently published a research article showing a cancer drug candidate to treat solid tumors. The article focused on the company’s clinical studies with STP707, a polypeptide nanoparticle formulation, and provided a foundation for further research to treat hepatocellular carcinoma and other solid tumors, […]